Caxton Associates LP Invests $1.09 Million in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Caxton Associates LP acquired a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 37,189 shares of the biopharmaceutical company’s stock, valued at approximately $1,087,000. Caxton Associates LP owned approximately 0.07% of Agios Pharmaceuticals at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Quest Partners LLC purchased a new stake in shares of Agios Pharmaceuticals in the fourth quarter valued at about $41,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Agios Pharmaceuticals by 352.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,469 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 5,040 shares during the period. NEOS Investment Management LLC purchased a new position in shares of Agios Pharmaceuticals during the fourth quarter valued at approximately $210,000. Entropy Technologies LP purchased a new position in shares of Agios Pharmaceuticals during the first quarter valued at approximately $286,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Agios Pharmaceuticals by 9.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,444 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 942 shares during the period.

Agios Pharmaceuticals Price Performance

AGIO traded down $0.49 during trading hours on Tuesday, reaching $46.94. 129,121 shares of the stock traded hands, compared to its average volume of 788,651. The firm’s fifty day simple moving average is $43.48 and its two-hundred day simple moving average is $34.00. Agios Pharmaceuticals, Inc. has a fifty-two week low of $19.80 and a fifty-two week high of $50.35.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.65) by $0.20. Agios Pharmaceuticals had a negative net margin of 1,199.26% and a negative return on equity of 41.41%. The business had revenue of $8.19 million during the quarter, compared to analyst estimates of $8.37 million. During the same period last year, the business earned ($1.47) EPS. The business’s revenue was up 46.0% on a year-over-year basis. Equities research analysts expect that Agios Pharmaceuticals, Inc. will post -2.15 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Monday, June 17th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $46.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, June 13th. StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 11th. Royal Bank of Canada increased their price objective on shares of Agios Pharmaceuticals from $44.00 to $53.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 4th. Finally, The Goldman Sachs Group increased their price objective on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a “neutral” rating in a research report on Tuesday, June 4th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, Agios Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $50.67.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.